CJC-1295 DAC Reconstitution: A Step-by-Step Guide

CJC-1295 DAC reconstitution is the preparation of a solution from a specified research material. The appropriate diluent, final volume, storage conditions, and use-by time must come from a validated method for that material; a 2 mg vial does not automatically call for 1–2 mL of bacteriostatic water.

Why CJC-1295 DAC Ships as a Powder

CJC-1295 is a growth hormone–releasing hormone (GHRH) analog. The "DAC" stands for Drug Affinity Complex, a maleimide linker that lets the peptide bind to serum albumin in the bloodstream. That binding is the reason CJC-1295 with DAC has a half-life measured in days instead of minutes.

Lyophilization can improve handling and storage for some formulations, but it does not establish room-temperature stability for an unspecified number of weeks. Solution stability must be assessed separately.

Supplies You Need Before You Start

• Check the labeled peptide amount, lot number, identity, and applicable analytical report before calculating concentration. The label is a nominal claim rather than an independent content assay.
• A compatible laboratory diluent, selected from the validated protocol. Bacteriostatic Water for Injection labeling describes benzyl-alcohol-preserved water, not proof that it is suitable for every peptide.
• Alcohol swabs, one per stopper per session
• A calibrated device with suitable resolution for the intended laboratory volume; confirm its scale and capacity.
• Sharps container and nitrile gloves

For laboratory reconstitution, use the exact material’s validated method, compatible diluent, and container capacity. Bacteriostatic water is not a universal requirement: its product labeling describes preserved water, but does not establish compatibility or a storage life for CJC-1295 DAC.

Availability at a pharmacy or online seller does not establish solvent compatibility. Product labeling and the laboratory method take priority over shopping advice.

Step-by-Step CJC-1295 DAC Reconstitution

1. Check the specified preparation temperature; do not assign an arbitrary warming time to every vial.
2. Wipe the rubber stoppers on both vials with a fresh alcohol swab and let them air dry.
3. Measure the protocol’s final solution volume and record it. Choosing 1 or 2 mL changes concentration but does not establish a safe human dose.
4. If the validated method calls for slow addition along the vial wall, follow that instruction using appropriate aseptic handling.
5. Avoid unnecessary foaming or handling outside the validated method; this article does not establish that a particular motion changes peptide yield.
6. Mix as the formulation instructions specify; a universal claim that shaking breaks CJC-1295 peptide chains is not established.
7. Appearance is only a limited handling observation. Unexpected particles or discoloration warrant stopping the laboratory procedure and checking the specification; a clear solution cannot establish identity, potency, endotoxin level, or sterility.
8. Label the preparation and store it under the protocol’s validated conditions.

Reconstitution Math: Concentration per Unit

The following calculations assume the stated peptide mass is accurate, dissolution is complete, and the specified volume is the final solution volume. They illustrate laboratory concentration and aliquot arithmetic, not a recommended human amount. Added diluent is only an approximation to final volume, and vessel capacity must be checked.

Nominal peptide mass	Final solution volume	Calculated concentration	Peptide in 10 U-100 volume markings (0.10 mL)
2 mg	1 mL	2,000 mcg/mL	200 mcg
2 mg	2 mL	1,000 mcg/mL	100 mcg
5 mg	1 mL	5,000 mcg/mL	500 mcg
5 mg	2.5 mL	2,000 mcg/mL	200 mcg

More dilute solutions may make small laboratory aliquots easier to measure, but must remain compatible with container capacity, assay conditions, and validated stability. U-100 markings indicate volume, not peptide potency.

Storage, Stability, and Shelf Life

Storage temperature and use-by time depend on the peptide formulation, solvent, concentration, container, and validated stability data. There is no universal “refrigerate for four weeks” or “freeze at −20°C” rule for every retail CJC-1295 vial. CDC’s opened multidose-vial guidance is not evidence that a newly mixed peptide remains chemically stable for 28 days.

The opened diluent’s discard date and the newly prepared peptide’s use-by date are separate questions. Neither a preserved diluent nor a CDC multidose-vial rule establishes 28 days of CJC-1295 solution stability.

How CJC-1295 DAC Compares to Other Options

Sustained stimulation does not mean GH pulses disappear. Ionescu and Frohman’s human sampling study found increased trough and mean GH with preserved pulse frequency and magnitude one week after CJC-1295 DAC. Calling the response a flat, nonpulsatile “GH bleed” misrepresents that result.

Compound	Relevant evidence	Administration context	Mixing implication
CJC-1295 DAC	Human half-life 5.8–8.1 days	Short controlled studies	Use material-specific formulation data
No DAC / Mod GRF (1-29)	Distinct non-albumin-binding material	DAC schedule cannot be transferred	Do not assume identical compatibility
Ipamorelin	Different receptor pathway	Combination regimen not validated here	No automatic same-vial compatibility

Ipamorelin acts through the ghrelin receptor pathway, whereas CJC-1295 acts through the GHRH receptor pathway. Different mechanisms do not establish a safe combination dose, compatibility in one vial, or superior sleep, recovery, or body composition. The cited DAC trials did not validate the online CJC-1295/ipamorelin schedules.

Safety, Legal Status, and Common Mistakes

A lot-matched report can document the sample tested, method, date, and result. It does not prove every vial has the same content, that a supplier-submitted sample was independently purchased, or that the material is sterile or clinically safe. Acceptance criteria should follow the laboratory’s intended assay, rather than a universal 98% purity threshold.

• Using an unvalidated mixing method: solvent, concentration, container, and agitation conditions should be documented; visible dissolution alone does not validate the preparation.
• Reusing needles or swabbing only one stopper
• Using a storage temperature or time without supporting stability information for that specific solution.
• Confusing milligrams with micrograms in the concentration math
• Treating a research-use label as proof of identity, tested content, or suitability for human use.

Anyone considering peptide use for personal health reasons should talk with a licensed healthcare professional first, especially if they take prescription medications or have an endocrine condition. Related research also covers CJC-1295 With DAC vs Ipamorelin: Key Differences and CJC-1295 DAC Cycle Length: How Long Should You Run It?.

COMMON QUESTIONS

Frequently Asked Questions

How much bacteriostatic water should I add to a 2 mg CJC-1295 DAC vial?

There is no universal diluent or volume for every 2 mg formulation. Follow the exact material’s validated laboratory method. For arithmetic only, verified 2 mg in a final 1 mL gives 2 mg/mL; in a final 2 mL it gives 1 mg/mL. Compatibility, complete dissolution, content, and vessel capacity are separate assumptions.

Does reconstituted CJC-1295 DAC need to be refrigerated?

Follow validated storage conditions for the exact formulation, diluent, concentration, and container. A generic 2–8°C or two- to four-week claim is not established for every CJC-1295 preparation. An opened diluent’s discard date is not evidence of the mixed peptide’s chemical stability.

Can I use sterile water instead of bacteriostatic water for CJC-1295 DAC?

Neither sterile water nor bacteriostatic water is universally interchangeable for this peptide. Solvent compatibility and chemical and microbiological stability require the exact preparation method. Benzyl alcohol in bacteriostatic water limits bacterial growth under labeled conditions, but does not prove sterility after mixing or a longer peptide shelf life.